secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-060660
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q3 2023: net loss $96.1M, Lilly deal up to $600M, pipeline on track
------------------------------------------------------------------------

- Net loss of $96.1M ($1.22 per share) vs $109.6M ($1.56) in Q3 2022; R&D $100M, G&A $25.4M.
- Cash and securities $1.0B as of Sep 30, 2023; expected runway into H2 2026 with Lilly proceeds.
- Lilly acquired opt-in rights to Verve's CV programs for $200M upfront + $50M equity + up to $350M milestones ($600M total).
- BEAM-101 first patient treatment by year-end 2023; initial data on multiple patients in 2024.
- BEAM-302 regulatory filing in Q1 2024; BEAM-301 IND in H1 2024; BEAM-201 initial data in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/0000950170-23-060660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023060660/beam-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer